Adobe

STAT+ | Despite its cancer-fighting mission, NCI starts to feel Trump administration budget ax

Trump cuts at NIH reach into the NCI: Closed programs, staff layoffs, disrupted clinical trials raise alarms over U.S. cancer research.

By Angus Chen and Jason Mast

Cancer before age 50 is increasing. A new study looks at which types

New study of early-onset cancer finds that the largest increases are in breast, colorectal, kidney, and uterine cancers.

By Associated Press

STAT+ | Vinay Prasad is outraged, and now at the FDA. How will biotech deal?

In this week's edition of "Adam's Biotech Scorecard," Adam takes a look at what the new FDA official may mean for drugmakers, treatments, and stocks.

By Adam Feuerstein

Milken Institute

Cancer innovation in ‘era of fear’: New AI tools meet old access barriers — and new funding cuts

Advances in AI, genomics, and liquid biopsy are reshaping oncology, but systemic gaps persist in access and funding, experts say.

By Elizabeth Cooney

FDA approves Verastem’s ovarian cancer treatment

Today's biotech news covers questions about the FDA's fast-tracking AI review, EMA investigating chikungunya vaccine safety, and more.

By Meghana Keshavan